FY2025 EPS Estimates for Surmodics Reduced by Zacks Research

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities researchers at Zacks Research decreased their FY2025 earnings per share estimates for Surmodics in a note issued to investors on Tuesday, July 1st. Zacks Research analyst D. Dey now expects that the company will post earnings per share of ($0.56) for the year, down from their prior forecast of ($0.54). The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.18) EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at ($0.09) EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The firm had revenue of $28.09 million for the quarter, compared to the consensus estimate of $32.23 million. Surmodics had a negative net margin of 16.34% and a negative return on equity of 7.10%.

Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th.

Surmodics Price Performance

Shares of SRDX stock traded up $0.99 during trading hours on Thursday, hitting $29.99. 140,852 shares of the company's stock were exchanged, compared to its average volume of 228,483. The company has a market capitalization of $428.79 million, a PE ratio of -21.57 and a beta of 1.31. The company has a current ratio of 5.14, a quick ratio of 3.99 and a debt-to-equity ratio of 0.27. Surmodics has a 12-month low of $26.00 and a 12-month high of $42.44. The business's 50 day simple moving average is $28.89 and its 200-day simple moving average is $31.70.

Institutional Investors Weigh In On Surmodics

A number of hedge funds and other institutional investors have recently modified their holdings of SRDX. Inspire Investing LLC grew its position in Surmodics by 11.3% during the 1st quarter. Inspire Investing LLC now owns 11,250 shares of the company's stock worth $343,000 after acquiring an additional 1,142 shares during the last quarter. Strs Ohio bought a new position in shares of Surmodics in the first quarter worth approximately $122,000. Murchinson Ltd. grew its holdings in shares of Surmodics by 5.8% in the first quarter. Murchinson Ltd. now owns 52,981 shares of the company's stock worth $1,618,000 after purchasing an additional 2,900 shares during the last quarter. Millennium Management LLC increased its stake in shares of Surmodics by 71.6% in the first quarter. Millennium Management LLC now owns 206,487 shares of the company's stock worth $6,304,000 after buying an additional 86,143 shares during the period. Finally, Alpine Global Management LLC raised its holdings in Surmodics by 70.0% during the 1st quarter. Alpine Global Management LLC now owns 85,000 shares of the company's stock valued at $2,595,000 after buying an additional 35,000 shares during the last quarter. Institutional investors own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).